J. Wollenhaupt

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Laure Gossec, Josef S Smolen, Sofía Ramiro et al. · Annals of the Rheumatic Diseases · 2016 · 913 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

Medicine, Pharmacology, Pharmacotherapy +12

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 590 citations

Medicine, Clinical Sciences, Immunology +14

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 520 citations

Medicine, Clinical Sciences, Pharmacotherapy +12

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Philip J. Mease, Roy Fleischmann, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2013 · 458 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +6